With snowballing healthcare spending and the emergence of new modalities of treatments, discussions are heating up around revisiting the scope of health coverage on pharmaceuticals, with the Ministry of Finance (MOF) and payers advocating the mantra of “large risks with…
HOME > BUSINESS
BUSINESS
- AstraZeneca Japan Adjusts Company Rules for Same-Sex, Common-Law Couples
August 16, 2019
- Otsuka Rings Up Double-Digit Growth in H1 Pharma Sales
August 9, 2019
- Takeda Seeks Japan Approval for Entyvio SC Form
August 9, 2019
- Ono Seeks Label Expansion for Onoact Sepsis-Associated Tachyarrhythmia
August 9, 2019
- Mitsubishi Tanabe’s Schizophrenia Drug Cariprazine Approved in 2 Asian Nations
August 9, 2019
- Mitsubishi Tanabe Submits PI Study Protocol for Spinal Cord Injury Treatment MT-3921 in US
August 9, 2019
- Sumitomo Dainippon Going Full Tilt for Napabucasin Colorectal Cancer Trial after Pancreatic Flop
August 8, 2019
- Mitsubishi Tanabe’s ALS Drug Gains Chinese Approval
August 8, 2019
- Meiji Launches 2 Santen Eye Drugs in Indonesia
August 8, 2019
- Life Science Institute’s Muse Cell Product Processing Facility Bags Manufacturing License
August 8, 2019
- Japan Ethical Drug Sales Up 0.2% in June: Crecon
August 8, 2019
- Novartis’ Entresto Filed in Japan for Chronic Heart Failure
August 7, 2019
- Keytruda Top-Selling Drug in Japan in April-June: IQVIA
August 7, 2019
- PIII Gets Underway for Astellas’ Hot Flash Drug Fezolinetant
August 7, 2019
- Mitsubishi Tanabe, Jichi Medical Univ. to Commence AMED-Funded Hemophilia Gene Therapy Research
August 7, 2019
- Rohto President “Frustrated” with Slow Pace of Rx-to-OTC Switches in Japan
August 7, 2019
- Suzuken, SanBio Join Forces for Commercial Distribution of Stem Cell Therapy
August 7, 2019
- Keytruda Keeps Top Spot in Drug Sales Ranking in July: Encise
August 7, 2019
- Gearing Up for Japan Debut, Daiichi Sankyo Mounting Push for AML Med Vanflyta
August 6, 2019
- Daiichi Sankyo’s Pexidartinib Bags 1st FDA Nod for Rare Joint Tumor
August 6, 2019
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…